Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and remains difficult to control once it advances beyond the kidney. Although immunotherapy, targeted drugs and combination regimens have improved outcomes for some patients, many tumors eventually resist treatment or continue to spread. A new study published in Genes & Immunity identifies a previously underappreciated driver of this behavior: a protein called SERPINH1, produced in large part by cancer-associated fibroblasts (CAFs) within the tumor microenvironment. The findings suggest that these supportive stromal cells are not passive bystanders but active regulators of tumor aggressiveness, helping malignant kidney cells acquire features associated with invasion and metastasis.
The research team led by Luo, Li and Wang used single-cell RNA sequencing data from ccRCC tumors obtained through the Gene Expression Omnibus database. Unlike conventional gene-expression analyses, which average signals across thousands or millions of cells, single-cell sequencing allows researchers to examine the molecular identity and behavior of individual cells within a tumor. This approach is particularly valuable in ccRCC, a disease known for extensive intratumoral heterogeneity. Different tumor-cell populations can coexist in the same lesion, displaying distinct genetic programs, metabolic states and responses to therapy. By mapping these individual cellular states, the investigators were able to identify a fibroblast population characterized by high SERPINH1 expression and examine how it interacted with cancer cells.
SERPINH1 encodes a collagen-associated molecular chaperone, also known as heat shock protein 47, which assists in the proper folding and processing of collagen within the endoplasmic reticulum. Its expression is often associated with extracellular-matrix production and tissue remodeling. In the ccRCC tumor microenvironment, however, the protein appears to have a broader role. The single-cell analysis indicated that CAFs were a major source of SERPINH1, a result that was subsequently confirmed using fibroblasts isolated directly from tumor tissue. This distinction is important because the same gene can be expressed by multiple cell types, and identifying its cellular origin can determine whether a potential therapy should target the cancer cells themselves, the surrounding stroma or the communication between them.
CAFs arise from resident fibroblasts and other precursor populations that become functionally reprogrammed by signals released from tumors. Once activated, they can produce structural proteins, growth factors, cytokines and enzymes that reshape the extracellular matrix and alter immune and vascular behavior. In many cancers, CAFs create a physical and biochemical environment that supports tumor growth while limiting drug penetration and influencing immune-cell activity. The new ccRCC study places SERPINH1 at the center of this stromal activity. Rather than simply reflecting the presence of activated fibroblasts, SERPINH1 appears to participate directly in the exchange of signals that makes tumor cells more mobile and potentially more invasive.
In laboratory experiments, SERPINH1 derived from CAFs increased transforming growth factor beta, or TGF-β, signaling in ccRCC cells. TGF-β is a multifunctional cytokine that can regulate cell proliferation, extracellular-matrix deposition, immune responses and tissue repair. In established tumors, persistent TGF-β activity frequently promotes epithelial-mesenchymal transition, a biological program known as EMT. During EMT, epithelial cells lose characteristics such as strong cell-to-cell adhesion and organized polarity, while acquiring mesenchymal traits that enhance motility, flexibility and tissue invasion. The investigators reported that CAF-derived SERPINH1 promoted EMT-related changes in ccRCC cells, linking a fibroblast-produced protein to a malignant transformation in tumor-cell behavior.
The study also uncovered a feedback mechanism that may help sustain this process. TGF-β released or induced in the tumor-cell compartment enhanced SERPINH1 secretion by CAFs. In turn, the additional SERPINH1 supplied by fibroblasts further elevated TGF-β activity in the cancer cells. Such reciprocal signaling loops can stabilize an aggressive tumor state because neither the stromal compartment nor the cancer-cell compartment acts alone. Once established, the loop may continually reinforce extracellular-matrix remodeling, EMT and other features associated with progression. This kind of cross-talk also helps explain why therapies directed only at malignant cells may produce incomplete responses: the surrounding microenvironment can preserve the signals that support tumor survival and dissemination.
The researchers tested the biological importance of SERPINH1 in cultured cells and in animal models of ccRCC. Their in vivo experiments showed that blocking SERPINH1 function suppressed features of malignant progression, supporting the conclusion that the protein is not merely a marker of aggressive fibroblasts. Instead, it may represent a functional vulnerability within the tumor ecosystem. The results do not establish that a SERPINH1-directed therapy is ready for clinical use, and the study does not provide evidence of efficacy in human patients. Translating the findings will require careful assessment of how SERPINH1 inhibition affects normal collagen production, wound healing and other physiological processes in which fibroblasts and extracellular-matrix regulation are essential.
The findings add to a growing view of cancer as an ecosystem rather than a collection of malignant cells acting independently. In ccRCC, the interaction between tumor cells and CAFs may influence whether the disease remains localized or develops invasive characteristics. Targeting this interaction could involve direct inhibition of SERPINH1, interference with TGF-β signaling, prevention of CAF activation or combinations that integrate stromal treatment with existing immunotherapies and molecularly targeted drugs. Each strategy presents challenges, because TGF-β has context-dependent effects and fibroblasts can exist in functionally diverse states. Future studies will need to determine which patients have SERPINH1-rich CAF populations, whether the protein can be detected reliably as a biomarker and whether disrupting the feedback loop improves responses without causing unacceptable toxicity.
By identifying CAFs as a central communication hub in ccRCC, the study offers a mechanistic explanation for how the tumor microenvironment can drive epithelial plasticity and disease progression. Its most significant contribution is the connection between a fibroblast-derived SERPINH1 signal and TGF-β-dependent EMT in kidney cancer cells. The work also reinforces the value of single-cell sequencing for uncovering interactions that conventional bulk-tissue analysis can obscure. If validated in larger studies, SERPINH1 could become both a biomarker of an aggressive stromal phenotype and a target for therapies designed to disable the supportive circuitry surrounding ccRCC. For now, the evidence remains preclinical, but it points toward a broader therapeutic principle: slowing cancer progression may require disrupting not only the tumor cells, but also the cellular partners that continually instruct them to become more dangerous.
Subject of Research: The role of SERPINH1-producing cancer-associated fibroblasts in epithelial-mesenchymal transition and malignant progression of clear cell renal cell carcinoma.
Article Title: SERPINH1 derived from cancer-associated fibroblasts promotes epithelial-mesenchymal transition in clear cell renal cell carcinoma
Article References: Luo, R., Li, S., Wang, H. et al. “SERPINH1 derived from cancer-associated fibroblasts promotes epithelial-mesenchymal transition in clear cell renal cell carcinoma.” Genes Immun (2026). https://doi.org/10.1038/s41435-026-00407-0
Image Credits: AI Generated
DOI: 10.1038/s41435-026-00407-0
Keywords: clear cell renal cell carcinoma, cancer-associated fibroblasts, SERPINH1, HSP47, TGF-β, epithelial-mesenchymal transition, tumor microenvironment, single-cell RNA sequencing, metastasis, cancer therapy
